Michel Biour

Learn More
P ioglitazone, a peroxisome prolifera-tor–activated receptor ␥ agonist, is a relatively new oral antidiabetes agent. It has been shown to decrease insulin resistance in patients with type 2 diabetes, resulting in lowered blood glucose concentrations and A1C values. It can be used alone or in combination with metformin or a sulfonylurea. The adverse effects(More)
  • 1